The global infantile spasms therapeutics market size reached US$ 3.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 4.2% during 2023-2028. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.
Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.
Infantile Spasms Therapeutics Market Trends:
The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global infantile spasms therapeutics market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on therapeutic class, drug type, dosage, route of administration, distribution channel, and end user.
Therapeutic Class Insights:
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the therapeutic class. This includes anticonvulsants, corticosteroids, and others. According to the report, anticonvulsants represented the largest segment.
Drug Type Insights:
- Adrenocorticotropic Hormone
- Others (Phase III)
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the drug type. This includes vigabatrin, adrenocorticotropic hormone, and others (phase III). According to the report, adrenocorticotropic hormone represented the largest segment.
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the dosage. This includes solid and liquid. According to the report, liquid represented the largest segment.
Route of Administration Insights:
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the route of administration. This includes oral, parenteral, and others. According to the report, parenteral represented the largest segment.
Distribution Channel Insights:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The report has provided a detailed breakup and analysis of the infantile spasms therapeutics market based on the route of administration. This includes hospital pharmacy, retail pharmacy, and online pharmacy. According to the report, hospital pharmacy represented the largest segment.
End User Insights:
A detailed breakup and analysis of the infantile spasms therapeutics market based on the distribution channel has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.
The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis
|Therapeutic Class Covered
||Anticonvulsants, Corticosteroids, Others
|Drug Type Covered
||Vigabatrin, Adrenocorticotropic Hormone, Other(Phase III)
|Route of Administration Covered
||Oral, Parenteral, and Others
|Distribution Channel Covered
||Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
|End User Covered
||Hospitals, Clinics, Others
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the infantile spasms therapeutics market from 2017-2028
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global infantile spasms therapeutics market.
- The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the infantile spasms therapeutics industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.